Abstract
D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 μg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven prostate cancer in whom hormonal therapy was indicated were recruited. Patients received either 30 or 100 μg given intramuscularly on three separate occasions over six weeks. Patients were followed up and blood was taken for estimation of serum testosterone, PSA and anti-GnRH antibody titre. Overall the drug was well tolerated. In 5 patients a significant reduction in serum testosterone and PSA was seen. Castrate levels of testosterone were achieved in 4 and maintained for up to 9 months. Patients with the highest antibody titre had the best response in terms of testosterone suppression. This study shows that it is possible to immunize a patient with prostate cancer against GnRH to induce castrate levels of testosterone. This state appears to be reversible. This novel form of immunotherapy may have advantages over conventional forms of hormonal therapy and further studies are warranted in order to try and increase the proportion of responders. © 2000 Cancer Research Campaign
Keywords: prostate cancer, hormonal therapy, anti-GnRH antibodies
Full Text
The Full Text of this article is available as a PDF (58.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akakura K., Bruchovsky N., Goldenberg S. L., Rennie P. S., Buckley A. R., Sullivan L. D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993 May 1;71(9):2782–2790. doi: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- Bradwell A. R., Harvey T. C. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet. 1999 Jan 30;353(9150):370–373. doi: 10.1016/S0140-6736(98)06469-1. [DOI] [PubMed] [Google Scholar]
- Bruchovsky N., Rennie P. S., Coldman A. J., Goldenberg S. L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990 Apr 15;50(8):2275–2282. [PubMed] [Google Scholar]
- Ferro V. A., Stimson W. H. Effects of adjuvant, dose and carrier pre-sensitisation on the immunisation efficacy of a GnRH analogue. Drug Des Discov. 1996 Dec;14(3):179–195. [PubMed] [Google Scholar]
- Gual C., Garza-Flores J., Menjivar M., Gutierrez-Najar A., Pal R., Talwar G. P. Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women. Fertil Steril. 1997 Feb;67(2):404–407. doi: 10.1016/S0015-0282(97)81932-2. [DOI] [PubMed] [Google Scholar]
- Guinan P., Toronchi E., Shaw M., Crispin R., Sharifi R. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology. 1982 Oct;20(4):401–403. doi: 10.1016/0090-4295(82)90464-2. [DOI] [PubMed] [Google Scholar]
- Halmos G., Arencibia J. M., Schally A. V., Davis R., Bostwick D. G. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol. 2000 Feb;163(2):623–629. [PubMed] [Google Scholar]
- Jacobs E., Watson S. A., Michaeli D., Ellis I. O., Robertson J. F. Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Br J Cancer. 1999 May;80(3-4):352–359. doi: 10.1038/sj.bjc.6690362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jayashankar R., Chaudhuri M. K., Singh O., Alam A., Talwar G. P. Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate. 1989;14(1):3–11. doi: 10.1002/pros.2990140103. [DOI] [PubMed] [Google Scholar]
- Jungwirth A., Pinski J., Galvan G., Halmos G., Szepeshazi K., Cai R. Z., Groot K., Vadillo-Buenfil M., Schally A. V. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 1997 Jun;33(7):1141–1148. doi: 10.1016/s0959-8049(97)00072-5. [DOI] [PubMed] [Google Scholar]